Repligen (NASDAQ:RGEN) Upgraded to “Moderate Buy” at Royal Bank Of Canada

Repligen (NASDAQ:RGEN) was upgraded by research analysts at Royal Bank Of Canada to a “moderate buy” rating in a research report issued to clients and investors on Thursday,Zacks.com reports.

RGEN has been the subject of several other reports. HC Wainwright upped their price target on shares of Repligen from $180.00 to $208.00 and gave the stock a “buy” rating in a report on Monday, March 23rd. Canaccord Genuity Group lowered their price target on shares of Repligen from $165.00 to $145.00 and set a “hold” rating for the company in a report on Monday, April 20th. Wall Street Zen downgraded shares of Repligen from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. Barclays upped their price target on shares of Repligen from $145.00 to $160.00 and gave the stock an “overweight” rating in a report on Wednesday, May 6th. Finally, Rothschild & Co Redburn set a $160.00 price target on shares of Repligen and gave the stock a “buy” rating in a report on Friday, April 17th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Repligen presently has a consensus rating of “Moderate Buy” and a consensus price target of $166.15.

Repligen Stock Down 0.5%

Shares of NASDAQ:RGEN opened at $102.87 on Thursday. The company has a fifty day moving average of $118.96 and a 200-day moving average of $142.18. The company has a market capitalization of $5.80 billion, a PE ratio of 114.30, a price-to-earnings-growth ratio of 1.99 and a beta of 1.09. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.78 and a current ratio of 9.20. Repligen has a 52-week low of $100.99 and a 52-week high of $175.77.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.10. The company had revenue of $194.26 million during the quarter, compared to the consensus estimate of $192.05 million. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The company’s revenue for the quarter was up 14.8% compared to the same quarter last year. During the same period in the prior year, the business earned $0.39 earnings per share. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. On average, equities analysts predict that Repligen will post 1.99 EPS for the current fiscal year.

Institutional Trading of Repligen

Institutional investors and hedge funds have recently bought and sold shares of the stock. Measured Wealth Private Client Group LLC acquired a new stake in Repligen in the third quarter valued at $29,000. Bayforest Capital Ltd acquired a new stake in Repligen in the fourth quarter valued at $32,000. Rachor Investment Advisory Services LLC acquired a new stake in Repligen in the fourth quarter valued at $33,000. Los Angeles Capital Management LLC acquired a new stake in Repligen in the fourth quarter valued at $36,000. Finally, CWM LLC increased its holdings in Repligen by 67.2% in the third quarter. CWM LLC now owns 336 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 135 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.